Doping in sport: The biomarkers are the best tools to measure its prevalence and to establish the individual monitoring of the athletes  by Saugy, M.
Parallel Session Abstracts
2013 e127
tory potency) can be retrieved from libraries within the simulator. 
However, the information on each patient (ie, demography, physi-
ology, genetics, enzyme abundances and activity, level of plasma 
proteins, kidney function, various drugs taken and their dosage 
information) are also required. Some of these are not available rou-
tinely and hold the key to “Clinical Oriented” applications (eg, in 
iPad and so on).
Disclosure of Interest: A. Rostami-Hodjegan: shareholder of Certara, 
Diurnal, and Zilico; grant/research support from a consortium of 
pharmaceutical companies; and other: part-time secondee to Simcyp 
(Certara).
Developing a stanDarDiseD prescription 
chart to reDuce error
P. Routledge*
Pharmacology, Therapeutics and Toxicology, Cardiff University, 
Cardiff, United Kingdom
Summary: Unfamiliarity is an important contributor to error, includ-
ing medication errors, some of which result in adverse events. Paper-
based inpatient prescription charts differ in different hospitals, and 
medical trainees move around health care systems, so they may be 
unfamiliar with such charts initially.
Standards for the design of inpatient prescriptions charts have 
recently been agreed by the Academy of Medical Royal Colleges 
in the United Kingdom.1 In several studies, standardization of pre-
scribing documents has been associated with significantly reduced 
medication errors in adults in Australia,2 as well as in some aspects of 
pediatric medicine. The introduction of a single inpatient prescription 
chart in Wales in 20043 and its subsequent continuing development 
will be described. The training resources developed to support the 
chart will also be discussed.
Standardization of prescribing standards, of acceptable abbrevia-
tions, and standardized training in prescribing can also all contribute 
to a reduction in medication errors and associated adverse events, 
including when electronic rather than paper-based prescriptions are 
written.
Disclosure of Interest: None declared.
references
1. Academy of Medical Royal Colleges 2011. Standards for the design 
of hospital in-patient prescription charts. http://www.aomrc.org.
uk/publications/reports-a-guidance.html. Accessed 10/07/2013.
2. Coombes I D , Reid C , McDougall D , et al. Pilot of a national 
inpatient medication chart in Australia: improving prescribing 
safety and enabling prescribing training. Br J Clin Pharmacol. 
2011;72:338–349.
3. Routledge P A . A national in-patient prescription chart: the 
experience in Wales 2004-2012. Br J Clin Pharmacol. 2012;74:561–
565.
the inDiviDualisation of cancer therapy 
in organ Dysfunction
M. Rudek*
Oncology, Johns Hopkins University, Baltimore, Maryland
Summary: Cancer patients with adequate hepatic or renal func-
tion are typically studied during drug development. The majority 
of anticancer agents are cleared by via hepatic or renal mechanisms. 
Therefore, dose adjustments would be anticipated in patients with 
organ dysfunction. However, when a drug is approved, dosing modi-
fication guidelines are often lacking for patients who have varying 
degrees of hepatic or renal dysfunction, especially moderate or severe 
dysfunction. In clinical practice, oncologists may start therapy with 
an empirically derived lower starting dose due to the perception that 
a patient with organ dysfunction would have poorer tolerability 
due to increased toxicity. The presentation will summarize: (1) A 
brief historical perspective of individualization of cancer therapy 
in organ dysfunction; (2) pathophysiology of organ dysfunction in 
cancer patients; (3) barriers to the conduct of clinical trials in this 
population; and (4) recent examples of dosing recommendations for 
anticancer agents.
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gene therapy approval process at eMa
S. Ruiz*
Spanish Medicines Agency (AEMPS), Madrid, Spain
Summary: In addition to the increasing number of biological and 
biotechnological medicinal products available for different clinical 
indications, the development of gene- and cell-based products offer 
alternative approaches for the prevention and treatment of human 
diseases. An increasing number of gene therapy and somatic cell ther-
apy products are already in clinical development for the treatment 
of inherited diseases, cancer, diabetes, Parkinson’s disease, and other 
neurodegenerative disorders. As gene and cell therapy products are 
presented as having properties for treating or preventing diseases in 
human beings, or that they may be used in or administered to human 
beings with a view to restoring, correcting, or modifying physiologi-
cal functions by exerting principally a pharmacologic, immunologic, 
or metabolic action, they are considered biological medicinal prod-
ucts within the meaning of Annex I to Directive 2001/83/EC of the 
European Parliament and of the Council of 6 November 2001 on 
the Community code relating to medicinal products for human use.
Regulation (EC) 1394/2007 introduces additional provisions to 
those laid down in Directive 2001/83/EC and regulates advanced 
therapies that are intended to be placed on the market in the EU 
Member States and either prepared industrially or manufactured by 
a method involving an industrial process. However, ATMP “prepared 
on a non-routine basis according to specific quality standards, and 
used within the same Member State in a hospital under the exclu-
sive professional responsibility of a medical practitioner, in order to 
comply with an individual medical prescription for a custom-made 
product for an individual patient” are excluded. EU Member States 
are currently developing the rules to apply to these products to guar-
antee their quality and safety.
A review of gene therapy medicinal products that have applied 
for marketing authorization application through the European 
Medicines Agency will be presented.
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Doping in sport: the bioMarkers are the 
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of the athletes
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Summary: The athlete biological passport (ABP) is an individual and 
longitudinal monitoring of biomarkers potentially linked to doping. 
clinical therapeutics
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This came naturally with the implementation of tests out of the com-
petition period of the athletes. For an athlete, it has been observed 
that the homeostasis of biosynthesis and metabolism of endogenous 
hormones was not disturbed by sports activity but of course will be 
influenced by the intake of similar substances. Actually, the passport 
has been defined as an individual and longitudinal observation of 
biomarkers. These markers need to belong to the biological cascade 
influenced by the application of forbidden hormones or, more gen-
erally, affected by biological manipulations that can improve the 
performance of the athlete.
Nowadays, only the hematologic passport of an athlete has been 
officially set up. This is a statistical representation of the longitu-
dinal follow-up of some blood biomarkers. This individual and 
longitudinal follow-up of blood parameters is of interest because 
the intraindividual variability is lower than the corresponding inter-
individual variability. Among the key points for the implementa-
tion of the ABP is its possibility to resist to the legal and scientific 
challenges. The ABP should be implemented in the most possible 
transparent way in the process and with the necessary independ-
ence between planning, interpretation, and result management of 
the passport.
To reach this transparency and efficiency, a new major actor has 
been introduced in the system to create a framework of independ-
ence: The athlete Passport Management Unit (APMU). The World 
Antidoping Agency (WADA) did implement new dedicated technical 
documents associated with the passport (hematologic module). This 
was done to allow the correct implementation of a profile that can 
resist any scientific or legal critics in following strictly some steps in 
the chain of production of the results and in the management of the 
interpretation of the passport.
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new insights into the MechanisMs of 
Dioxin toxicity in huMans
J.-H. Saurat*
Offices R&D, Geneva, Switzerland
Summary: Several million people are exposed to dioxin and dioxin-
like compounds, primarily through food consumption. Skin lesions 
historically called ‘‘chloracne’’ are the most specific sign of abnor-
mal dioxin exposure and classically used as a key marker in humans. 
We followed up for 5 years a man who had been exposed to the 
most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
at a single oral dose of 5 million-fold more than the accepted 
daily exposure in the general population. We adopted a molecu-
lar medicine approach, aimed at identifying appropriate therapy. 
Skin lesions, which progressively covered up to 40% of the body 
surface, were found to be hamartomas, which developed parallel 
to a complete and sustained involution of sebaceous glands, with 
concurrent transcriptomic alterations pointing to the inhibition of 
lipid metabolism and the involvement of bone morphogenetic pro-
teins signaling. Hamartomas created a new compartment that con-
centrated TCDD up to 10-fold compared with serum and strongly 
expressed the TCDD-metabolizing enzyme cytochrome P-450 1A1, 
thus representing a potentially significant source of enzymatic activ-
ity, which may add to the xenobiotic metabolism potential of the 
classical organs such as the liver. This historical case provides a 
unique set of data on the human tissue response to dioxin for the 
identification of new markers of exposure in human populations. 
The herein discovered adaptive cutaneous response to TCDD also 
points to the potential role of the skin in the metabolism of food 
xenobiotics.
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the new zealanD centre for aDverse 
Drug reactions Monitoring: a source  
of practice-baseD eviDence
R.L. Savage*
Preventive and Social Medicine, University of Otago, Dunedin, 
New Zealand
Summary: In New Zealand, there has been discussion around the 
value of evidence-based medicine in primary care and the case for 
complementary practice-based evidence that could feed back into 
the evidence from clinical trials on the generality and applicability 
of the interventions in the “real-life” context.1 It is clear that data-
bases of adverse drug reaction (ADR) reports are, in fact, a source 
of practice-based evidence.
In 1965, New Zealand became 1 of the first countries to collect 
and assess reports submitted by health professionals of suspected 
ADRs in individual patients. This collection is the database of the 
Centre for Adverse Reactions Monitoring (CARM) based in the 
New Zealand Pharmacovigilance Centre. Distinctive features of the 
New Zealand database are the high proportion of well-documented 
reports, and, frequently, the highest reporting rate/population in 
international comparisons. New Zealand was also a founding mem-
ber of the WHO International Drug Monitoring Programme.
Databases of ADRs were established to generate hypotheses to be 
tested about previously unrecognized adverse reactions and interac-
tions. Occasionally, they contain sufficient evidence in themselves. 
They can also identify prescribing practices that might increase the 
potential for ADRs to occur. They can feed back into guidelines the 
consequences of their use or nonuse and identify unexpected prob-
lems that arise with issues such as pathways to accessing funded med-
icines. Well-documented ADR reports can also highlight risk factors, 
thus providing a valuable contribution to risk/benefit assessments in 
individual patients. Examples from the New Zealand database and 
from international collaboration will be discussed that support the 
use of ADR reports as practice-based evidence in a nonhierarchical 
system in which case reports and case series, observational studies, 
and randomized clinical trials contribute in a flexible relationship 
depending on the issue under investigation.
One of the major challenges in optimizing the contribution of 
ADR databases to clinical practice is the provision of feedback that 
aids prescribing and also stimulates the quality as well as quantity 
of reporting.
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risk perception aMong health care 
professionals anD the public: experience 
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Summary: Risk perception associated with medicines information 
affects drug therapy and drug adherence. One problem is inconsist-
encies between sources providing medicines information, which give 
